Arrowhead Pharmaceuticals, Inc. – NASDAQ:ARWR
Arrowhead Pharmaceuticals stock price today
$19.81
+0.84
+4.48%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Arrowhead Pharmaceuticals stock price monthly change
-32.55%
month
Arrowhead Pharmaceuticals stock price quarterly change
-32.55%
quarter
Arrowhead Pharmaceuticals stock price yearly change
-38.90%
year
Arrowhead Pharmaceuticals key metrics
Market Cap | 2.41B |
Enterprise value | 2.66B |
P/E | -17.37 |
EV/Sales | 9.58 |
EV/EBITDA | -19.55 |
Price/Sales | 9.99 |
Price/Book | 7.37 |
PEG ratio | 0.76 |
EPS | -2.54 |
Revenue | N/A |
EBITDA | -261.08M |
Income | -289.25M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -55.51% |
Oper. margin | -56.52% |
Gross margin | 11.64% |
EBIT margin | -56.52% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeArrowhead Pharmaceuticals stock price history
Arrowhead Pharmaceuticals stock forecast
Arrowhead Pharmaceuticals financial statements
Average Price Target
$37
Potential upside: 86.77%
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 146.26M | 48.67M | 33.28% |
|---|---|---|---|
| Jun 2023 | 15.82M | -102.94M | -650.53% |
| Sep 2023 | 16.09M | -109.67M | -681.36% |
| Mar 2024 | 0 | -125.3M |
| 2023-05-02 | 0.45 | 0.45 |
|---|
| Mar 2023 | 891308000 | 426.20M | 47.82% |
|---|---|---|---|
| Jun 2023 | 795856000 | 413.87M | 52% |
| Sep 2023 | 765552000 | 478.39M | 62.49% |
| Mar 2024 | 955150000 | 459.74M | 48.13% |
| Mar 2023 | -31.67M | -36.06M | 520K |
|---|---|---|---|
| Jun 2023 | -21.44M | -9.90M | 1.80M |
| Sep 2023 | -25.25M | 30.50M | 152K |
| Mar 2024 | -92.37M | -268.93M | 430.77M |
Arrowhead Pharmaceuticals alternative data
| Aug 2023 | 397 |
|---|---|
| Sep 2023 | 397 |
| Oct 2023 | 397 |
| Nov 2023 | 397 |
| Dec 2023 | 397 |
| Jan 2024 | 525 |
| Feb 2024 | 525 |
| Mar 2024 | 525 |
| Apr 2024 | 525 |
| May 2024 | 525 |
| Jun 2024 | 525 |
| Jul 2024 | 525 |
Arrowhead Pharmaceuticals other data
65.16%
-0.55%
of ARWR is owned by hedge funds
295
-9
68.11M
-51.65K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 186217 |
| Mar 2024 | 3000 | 40000 |
| Apr 2024 | 0 | 6000 |
| May 2024 | 0 | 1799 |
| Jul 2024 | 0 | 9394 |
| Dec 2024 | 0 | 61311 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ANZALONE CHRISTOPHER RICHARD director, officer.. | Common Stock | 12,563 | $19.59 | $246,109 | ||
Sale | ANZALONE CHRISTOPHER RICHARD director, officer.. | Common Stock | 12,653 | $20.52 | $259,640 | ||
Sale | ANZALONE CHRISTOPHER RICHARD director, officer.. | Common Stock | 8,260 | $21.74 | $179,572 | ||
Sale | ANZALONE CHRISTOPHER RICHARD director, officer.. | Common Stock | 5,799 | $22.12 | $128,274 | ||
Sale | WADDILL WILLIAM D. director | Common Stock | 3,747 | $22.04 | $82,584 | ||
Sale | GIVEN DOUGLAS B director | Common Stock | 547 | $22.04 | $12,056 | ||
Sale | WADDILL WILLIAM D. director | Common Stock | 3,748 | $21.9 | $82,081 | ||
Sale | GIVEN DOUGLAS B director | Common Stock | 5,000 | $21.9 | $109,500 | ||
Sale | VAKIENER VICTORIA director | Common Stock | 8,994 | $21.91 | $197,059 | ||
Sale | OLIVER TRACIE officer: Chief Commercial Officer | Common Stock | 9,394 | $25.28 | $237,480 |
| Patent |
|---|
Application Filling date: 5 Apr 2022 Issue date: 28 Jul 2022 |
Grant Filling date: 31 May 2019 Issue date: 12 Jul 2022 |
Application RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use Filling date: 8 Jan 2020 Issue date: 30 Jun 2022 |
Application Filling date: 10 Nov 2021 Issue date: 2 Jun 2022 |
Application Filling date: 7 Feb 2022 Issue date: 26 May 2022 |
Application Filling date: 3 Feb 2022 Issue date: 19 May 2022 |
Application Filling date: 30 Jun 2021 Issue date: 21 Apr 2022 |
Application Filling date: 23 Dec 2021 Issue date: 14 Apr 2022 |
Application Filling date: 29 Nov 2021 Issue date: 24 Mar 2022 |
Application Filling date: 17 Nov 2021 Issue date: 17 Mar 2022 |
| Quarter | Transcript |
|---|---|
| Q2 2024 9 May 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 6 Feb 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Nov 2023 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Aug 2023 | Q3 2023 Earnings Call Transcript |
Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
New And Improved Novartis
Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCD
Arrowhead Pharmaceuticals Remains A Buy For Pipeline Potential
Arrowhead: A Compelling Investment In RNAi Therapeutics With Significant Upside Potential
Arrowhead Pharmaceuticals Requires Caution
Arrowhead Pharmaceuticals: Good Work In Progress
Arrowhead Pharmaceuticals: Olpasiran's Impressive Phase 2 Data
-
What's the price of Arrowhead Pharmaceuticals stock today?
One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $19.81.
-
When is Arrowhead Pharmaceuticals's next earnings date?
Unfortunately, Arrowhead Pharmaceuticals's (ARWR) next earnings date is currently unknown.
-
Does Arrowhead Pharmaceuticals pay dividends?
No, Arrowhead Pharmaceuticals does not pay dividends.
-
How much money does Arrowhead Pharmaceuticals make?
Arrowhead Pharmaceuticals has a market capitalization of 2.41B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 98.52% to 3.55M US dollars. Arrowhead Pharmaceuticals made a loss 599.49M US dollars in net income (profit) last year or $0.45 on an earnings per share basis.
-
What is Arrowhead Pharmaceuticals's stock symbol?
Arrowhead Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ARWR".
-
What is Arrowhead Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Arrowhead Pharmaceuticals?
Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Arrowhead Pharmaceuticals's key executives?
Arrowhead Pharmaceuticals's management team includes the following people:
- Dr. Christopher R. Anzalone Chief Executive Officer, Pres & Director(age: 56, pay: $1,610,000)
- Mr. Kenneth A. Myszkowski Chief Financial Officer(age: 59, pay: $690,300)
- Dr. Javier San Martin M.D. Chief Medical Officer(age: 60, pay: $673,570)
-
How many employees does Arrowhead Pharmaceuticals have?
As Jul 2024, Arrowhead Pharmaceuticals employs 525 workers.
-
When Arrowhead Pharmaceuticals went public?
Arrowhead Pharmaceuticals, Inc. is publicly traded company for more then 31 years since IPO on 16 Dec 1993.
-
What is Arrowhead Pharmaceuticals's official website?
The official website for Arrowhead Pharmaceuticals is arrowheadpharma.com.
-
Where are Arrowhead Pharmaceuticals's headquarters?
Arrowhead Pharmaceuticals is headquartered at 177 East Colorado Boulevard, Pasadena, CA.
-
How can i contact Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals's mailing address is 177 East Colorado Boulevard, Pasadena, CA and company can be reached via phone at +62 630 43400.
-
What is Arrowhead Pharmaceuticals stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Arrowhead Pharmaceuticals in the last 12 months, the avarage price target is $37. The average price target represents a 86.77% change from the last price of $19.81.
Arrowhead Pharmaceuticals company profile:
Arrowhead Pharmaceuticals, Inc.
arrowheadpharma.comExchange:
NASDAQ
Full time employees:
525
Industry:
Biotechnology
Sector:
Healthcare
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
177 East Colorado Boulevard
Pasadena, CA 91105
Pasadena, CA 91105
CIK: 0000879407
ISIN: US04280A1007
CUSIP: 04280A100
